{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:23:59Z","timestamp":1776662639734,"version":"3.51.2"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare but have been increasing in incidence. Limited data on the long-term outcomes of patients with these tumors are available.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this study, we used population-based data from the National Cancer Institute to assess long-term disease-specific survival (DSS) of patients who have undergone surgery for nonmetastatic disease. All patients with NETs of the stomach, small intestine, colon, rectum, appendix, and pancreas diagnosed between 1988 and 2009 were identified from the Surveillance, Epidemiology and End Results registry. Staging was derived from Surveillance, Epidemiology and End Results data using the European Neuroendocrine Tumor Society guidelines. Cases with incomplete staging data were excluded, along with those with stage IV disease, or those who did not undergo surgical resection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Kaplan-Meier analyses were constructed to determine DSS. Analyses were further stratified according to tumor site, stage at diagnosis, and tumor grade. Overall, 13,348 patients with GEP-NETs meeting the inclusion criteria were identified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>There were excellent outcomes for most GEP-NET patients, with a 20-year DSS of greater than 75% across all sites and stages. Pancreatic tumors had the worst outcomes, but DSS remains greater than 50% at 20 years.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000001005","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T23:02:15Z","timestamp":1517785335000},"page":"321-325","source":"Crossref","is-referenced-by-count":28,"title":["Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.1097","volume":"47","author":[{"given":"Weiwei","family":"Chi","sequence":"first","affiliation":[{"name":"From the *Department of Medicine, \u2020Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; \u2021Division of Medical Oncology and Hematology, \u00a7Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; \u2225Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia; and \u00b6Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard R.P.","family":"Warner","sequence":"additional","affiliation":[{"name":"From the *Department of Medicine, \u2020Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; \u2021Division of Medical Oncology and Hematology, \u00a7Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; \u2225Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia; and \u00b6Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Chan","sequence":"additional","affiliation":[{"name":"From the *Department of Medicine, \u2020Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; \u2021Division of Medical Oncology and Hematology, \u00a7Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; \u2225Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia; and \u00b6Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"From the *Department of Medicine, \u2020Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; \u2021Division of Medical Oncology and Hematology, \u00a7Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; \u2225Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia; and \u00b6Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[{"name":"From the *Department of Medicine, \u2020Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; \u2021Division of Medical Oncology and Hematology, \u00a7Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; \u2225Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia; and \u00b6Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Strosberg","sequence":"additional","affiliation":[{"name":"From the *Department of Medicine, \u2020Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; \u2021Division of Medical Oncology and Hematology, \u00a7Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; \u2225Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia; and \u00b6Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wisnivesky","sequence":"additional","affiliation":[{"name":"From the *Department of Medicine, \u2020Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; \u2021Division of Medical Oncology and Hematology, \u00a7Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; \u2225Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia; and \u00b6Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle K.","family":"Kim","sequence":"additional","affiliation":[{"name":"From the *Department of Medicine, \u2020Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY; \u2021Division of Medical Oncology and Hematology, \u00a7Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; \u2225Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia; and \u00b6Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20231016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"bib2-20231016","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib3-20231016","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.ejso.2016.07.137","article-title":"Localized high-grade gastroenteropancreatic neuroendocrine tumors: defining prognostic and therapeutic factors for a disease of increasing clinical significance","volume":"42","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"bib4-20231016","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization","volume":"12","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"bib5-20231016","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ejso.2015.02.011","article-title":"Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastro-enteric and pancreatic locations","volume":"41","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"bib6-20231016","doi-asserted-by":"crossref","first-page":"7798","DOI":"10.1158\/1078-0432.CCR-08-0734","article-title":"Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution","volume":"14","year":"2008","journal-title":"Clin Cancer Res"},{"key":"bib7-20231016","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours","volume":"15","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"bib8-20231016","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/cncr.25855","article-title":"Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome","volume":"117","year":"2011","journal-title":"Cancer"},{"key":"bib9-20231016","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.bjc.6603699","article-title":"The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract","volume":"96","year":"2007","journal-title":"Br J Cancer"},{"key":"bib10-20231016","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jamcollsurg.2013.12.035","article-title":"A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors","volume":"218","year":"2014","journal-title":"J Am Coll Surg"},{"key":"bib11-20231016","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2016.12.032","article-title":"Aggressive surgical approach to the management of neuroendocrine tumors: a report of 1,000 surgical cytoreductions by a single institution","volume":"224","year":"2017","journal-title":"J Am Coll Surg"},{"key":"bib12-20231016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jso.23205","article-title":"Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype","volume":"107","year":"2013","journal-title":"J Surg Oncol"},{"key":"bib13-20231016","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","year":"2006","journal-title":"Virchows Arch"},{"key":"bib14-20231016","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"451","year":"2007","journal-title":"Virchows Arch"},{"key":"bib15-20231016","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jnci\/djs208","article-title":"TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study","volume":"104","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"bib17-20231016","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","year":"2013","journal-title":"Pancreas"},{"key":"bib18-20231016","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000335595","article-title":"ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms","volume":"95","year":"2012","journal-title":"Neuroendocrinology"},{"key":"bib19-20231016","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","article-title":"ENETS Consensus Guidelines Update for gastroduodenal neuroendocrine neoplasms","volume":"103","year":"2016","journal-title":"Neuroendocrinology"},{"key":"bib20-20231016","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS Consensus Guidelines Update for neuroendocrine neoplasms of the jejunum and ileum","volume":"103","year":"2016","journal-title":"Neuroendocrinology"},{"key":"bib21-20231016","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000335594","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms","volume":"95","year":"2012","journal-title":"Neuroendocrinology"},{"key":"bib22-20231016","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000443166","article-title":"ENETS Consensus Guidelines Update for colorectal neuroendocrine neoplasms","volume":"103","year":"2016","journal-title":"Neuroendocrinology"},{"key":"bib23-20231016","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000335587","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors","volume":"95","year":"2012","journal-title":"Neuroendocrinology"},{"key":"bib24-20231016","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","year":"2012","journal-title":"Neuroendocrinology"},{"key":"bib25-20231016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS Consensus Guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","year":"2016","journal-title":"Neuroendocrinology"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006676-201803000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:20:19Z","timestamp":1697426419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201803000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001005","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"value":"1536-4828","type":"electronic"},{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}